3 trends in biotech to watch in 2019

(By Damian Garde for STAT)

On paper, biotech had quite a year in 2018.

Futuristic medicines demonstrated their worth in clinical trials and now look poised to become revolutionary therapies. Scrappy upstarts developed novel drugs without the need for their pharma forebears. And investors were game to fund the whole endeavor, buying into initial public offerings that kept the industry churning.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.